Nutra Pharma Corp Reports $2.05 Million Net Loss and Decline in Revenue for Fiscal Year 2025

Nutra Pharma Corp reported a net loss of $2.05 million for the fiscal year ending December 31, 2025, an increase of 59.25% from the previous year's loss of $1.29 million. The company's revenues for 2025 totaled $385,307, a slight decrease from $392,150 in 2024. The decline in revenue was attributed to reduced sales volumes and pricing adjustments, particularly in sales to related parties. The cost of sales rose significantly to $183,679, compared to $84,827 in 2024, leading to a gross profit margin of 51.03%, down from 63.07% the previous year. The increase in costs was primarily due to higher manufacturing expenses and the addition of inventory quality control personnel.

In terms of operational developments, Nutra Pharma has focused on expanding its product offerings and manufacturing capabilities. The company has transitioned to in-house manufacturing, which it believes will reduce costs and improve margins. In 2025, Nutra Pharma began producing private label products for Avini Health, contributing to its revenue stream. The company also launched Plus Relief for Pets, a private label version of its Pet Pain-Away product, in October 2023. Despite these efforts, Nutra Pharma's overall sales have been inconsistent, and the company continues to face challenges in achieving sufficient revenue to cover its operating expenses.

The company has also been actively pursuing international market opportunities, particularly in India, where it has entered into a business collaboration agreement to support its expansion efforts. Nutra Pharma is seeking to complete the registration process for its products in various international markets, including Canada and Europe. However, the company has faced delays in its clinical studies and product approvals due to funding constraints, which have hindered its ability to capitalize on these opportunities.

Looking ahead, Nutra Pharma's management has expressed concerns about its ability to continue as a going concern without securing additional financing or achieving significant sales growth. The company reported a working capital deficit of $16.81 million as of December 31, 2025, and has indicated that it will require approximately $1.5 million to fund its operations over the next twelve months. The management's strategy includes increasing sales of its existing products and seeking additional funding to support its growth initiatives. However, the company acknowledges the uncertainty surrounding its ability to raise the necessary capital and the potential impact on its future operations.